summari expect report larg in-lin provid
guidanc could exceed consensu forecast estim
revenu ep essenti in-lin
street forecast impli organ growth acceler
across unit estim total revenu
organ growth believ reason base jnj
growth momentum rais ep estim
consensu high-end forecast assum
underli growth plu atln fx tailwind
analysi suggest jnj ep could exceed
although expect initi guidanc conserv
possibl rang oper growth
note also track perform key drug us
base im data rais price target
base new ep estim
see larg in-lin estim sale
consensu organ growth vs
ex-prior period price adjust ppa
assum growth acceler three busi vs
pharma estim organ growth vs
analysi im data suggest key us drug
perform in-lin expect consum
estim organ growth vs medic
devic estim organ growth vs
overal sale consensu impli organ
growth estim ex-ppa adjust
forecast assum stabl growth pharmaceut
improv growth medic devic consum
expect improv growth driven new launch
accret recent acquisit like amo vogu jnj
guidanc impli sale growth suggest
assumpt reason
potenti upsid street ep new ep
assum underli growth atln accret
fx benefit oper growth see potenti
upsid high-end estim stronger underli
growth higher fx benefit great impact atln
accret guidanc tax reform benefit
potenti higher net incom believ jnj ep
could ultim exceed expect initi guidanc
conserv possibl rang
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani prioriti stock list
compani data secur llc estim reuter
us pharma consum perform larg in-lin expect plan
report result estim total sale consensu ep
estim impli organ growth ppa-adjust
forecast also includ fx tailwind materi chang sinc jnj report
octob model assum growth acceler across three jnj busi vs
pharma estim organ sale growth vs consum estim
organ growth vs analysi im data suggest key us
drug perform in-lin expect review nielsen data point potenti
improv us consum growth direct consist model medic devic
estim organ growth vs
fx tailwind seem unchang analysi suggest fx tailwind rel
unchang sinc jnj report estim fx benefit bottom-lin approxim
recal guid fx tailwind top-lin ep benefit full year
im sale suggest larg in-lin perform us pharmaceut analysi im data
key drug suggest potenti upsid remicad zytiga gener in-lin perform
rest product figur rais us sale forecast remicad
zytiga potenti modest upsid product uptravi
believ magnitud upsid insuffici warrant rais number increas
sale estim monthli product tracker detail start page
price increas price increas appear consist recent histori
review wac wholesal acquisit cost price increas key us drug earli
consist histori rais price across portfolio increas
took select price increas year earli rais wac key us
drug price increas rang darzalex remicad invokana
figur also increas price newest drug tremfya earli januari also rais
wac three key atln drug
compani report secur llc estim organ growth adjust fx acquisitions/divestitur extra sell day prior price adjust ppa pharma venezuela note amo acqusit includ ex-fx growth rate atln acquisit includ ex-fx growth rate ex-fx growthorgan growth busi segmentsoct nov growthim estimate estpharma salesremicad im health medi-span clinic drug inform llc compani report secur llc estim price increas effect extrapol assum oct nov repres sale growthwac increas johnson johnson
consum perform larg in-lin jnj consum organ growth acceler
ww partli reflect easier comp call manag
note global categori growth remain rel soft analysi aggreg nielsen
data seem suggest jnj us consum busi improv
modestli growth yr/yr figur aggreg nielsen data
appear trend direct consist report sale organ growth time figur c-
forecast ww consum sale organ growth vs includ
flattish us sale vs
nielsen sale base aggreg data
nielsen sale base aggreg data
expect top-lin growth acceler current estim total
revenu organ growth oper estim
adjust prior period price adjust ppa sale estim ahead consensu
expect guid conserv start year typic believ rang
organ growth would reason figur estim impli organ sale
growth guidanc ppa-adjust growth first month
believ growth momentum exit bode well given guidanc jnj
histori comfort underli growth outlook fx analysi suggest
currenc upsid could drive report sale guidanc expect
histori guidanc adjust adjust adjust
adjust growth adjust ppa
atln deal close late june contribut sale
handicap potenti gener zytiga risk forecast us zytiga sale
assum gener competit octob stay expir believ
assumpt hold even lose ipr inter part review decis near-term
would appeal decis howev understand summari judgement hear
schedul earli februari patent lawsuit neg decis court would
also appeal could also end stay allow gener launch sooner
assum gener start downsid scenario would reduc sale estim
drag overal sale growth ep downsid els equal howev
believ suffici cushion absorb least impact earlier
apalutamid launch could anoth top-lin higher accret atln greater
fx tailwind benefit tax reform believ jnj guidanc unlik assum gener
zytiga competit least octob
expect sale growth acceler medic devic consum estim
underli sale growth estim ex-ppa medic
devic vs estim consum vs estim figur
jnj medic devic growth would still lag market jnj consum
growth would roughli in-lin overal market expect improv year/year growth medic
devic consum driven impact new product launch continu invest full
year impact acquisit like amo vogu organ
organ growth defin ex-fx venezuela impact differ ship day prior period price
adjust ppa pharma hep-c
guid organ growth without adjust ppa adjust ppa estim
growth guidanc closer
see ep guidanc exceed consensu expect rais ep
estim cent consensu exclud atln accret
fx benefit forecast impli ep growth nearli underli nearli oper
includ atln forecast may prove conserv grow underli ep mid-
high-singl digit rang recent year figur base analysi expect jnj ep
could exceed oper growth said expect guid conserv
start year like see ep guidanc rang would impli
oper ep growth includ atln organ ep growth atln exclud
benefit fx tax reform figur anticip fx tax reform benefit
hard quantifi potenti magnitud upsid expect reinvest least portion
benefit
atln deal accret guidanc
histori guidanc ex-atln adjust estim year
assum tax rate reduc expect reinvest sizeabl portion upsid
see sever sourc potenti ep upsid includ tax reform potenti upsid
ep estim includ stronger underli growth assum growth could add
forecast fx benefit could greater current estim recent analysi
suggest tailwind although like reinvest upsid atln accret
estim low-end jnj guidanc could even better
addit cost save lower tax rate coupl hundr basi point
consensu outlook yet estim tax rate reduct could add jnj bottom-
line howev would expect reinvest signific portion tax benefit thu reduc
net impact bottom-lin final model assum net incom fall nearli
may also prove conserv suggest past
incom fall cliff compani continu evalu portfolio
fx tailwind may underst consensu outlook fx went top-lin
bottom-lin headwind start year neutral sales/modest ep tailwind
current assum fx tailwind top-lin bottom-lin
updat fx analysi suggest fx benefit could closer top-lin translat
ep impact better math current consensu ep estim
 compani report secur llc estim fx chang benefit drag fx headwind increas fx headwind decreas ad tax benefit fx chang headwind tailwind oper ep growthreport epsepslowmidhighour report ep atln organ underli atln oper fx tax reform report compani report factset secur llc estimatesnot assum impact cordi divestitur anima close neutral ep medic technolog
impli growth exclud atln accret believ littl fx impact
street forecast ep estim also impli underli ep growth
expect pharmaceut pipelin remain spotlight
achiev key pharmaceut regulatori clinic mileston set may analyst
day among fda approv tremfya psoriasi present posit compass data
xarelto posit top-lin data interim analysi alcyon studi darzalex front-lin
multipl myeloma first regulatori file apalutamid non-metastat castration-resist
prostat cancer nmcrpc expect mileston yield increment growth opportun
jnj pharmaceut busi new approv launch also expect see addit
meaning progress jnj late-stag pipelin potenti file clinic data
present figur host call mathai mammen md phd global head scienc
develop janssen discuss jnj strategi pipelin highlight
impact biosimilar remicad still limit im data show biosimilar remicad continu
ramp slowli sale increas januari may novemb
figur recent entri second biosimilar materi chang trajectori biosimilar
penetr time im sale show remicad declin modestli
averag monthli sale prior month averag sale october/novemb
slightli wors report jan-sep us remicad sale declin benign
jnj initi expect potenti sale declin forecast us remicad sale ex-
export declin appear conserv recent im sale trend increas
us remicad sale estim ww sale yr/yr declin
court file earlier suggest celltrion buy cell media facil
singapor instead us could avoid infring jnj us patent patent
trial delay possibl addit earli septemb celltrion receiv
fda incheon korea facil inflectra manufactur observ
indic celltrion follow regulatori oblig consult
believ could result warn letter and/or potenti slow celltrion manufactur process
constrain suppli least would expect competitor use rais doubt
celltrion inflectra help remicad maintain share see note
celltrion manufactur issu could help remicad date addit detail also
septemb celltrion us partner file lawsuit alleg contract
remicad anti-competit block sale biosimilar would expect litig
materi impact remicad growth biosimilar penetr time
darzalex share line multipl myeloma mm dip expect move front-lin use
relapsed/refractori r/r mm patient receiv least one prior therapi novemb
sinc drug share line treatment jump septemb
dip share novemb accord brandimpact survey figur line
darzalex larg remain share rang close second velcad share
figur darzalex hold overal market share survey despit share line
use expect darzalex penetr line continu rise approv front-lin use
possibl help drive uptak line overal share gain present posit
interim data alcyon trial line use american societi hematolog file
approv late estim darzalex sale includ us sale
yr/yr growth latter seem reason base recent im sale trend
imbruvica front-lin cll use continu drive growth front-lin mcl next first-lin cll
chronic lymphocyt leukemia indic remain key driver imbruvica adopt six
total approv indic call indic imbruvica market leader across
line therapi cll patient share line vs patient share
line plu base roll data growth averag weekli
averag figur partnership book sale book ou sale
split global profit interim data front-lin mcl studi could lead fda approv next
year data posit estim us imbruvica revenu impli end-us
sale growth seem reason base im sale trend estim ww
imbruvica revenu impli end-us sale
invokana/invokamet rx volum market share continu fall invokana franchis
volum fell novemb compar declin juli post-ada growth januari
figur weekli im data show similar trend
use revlimid velcad plu dexamethason
novemb vs may ada figur invokana/invokamet rx volum declin
acceler sinc canvas/canvas-r outcom data ada american diabet associ
meet june recal data show invokana effect reduc cardiovascular
risk also led significantli higher rate amput fractur patient treatment
within class invokana/invokamet nrx share also continu slide reach
novmeb vs juli januari comparis competitor azn farxiga/xiguo xr
remain rang bi/lli jardianc franchis share climb
januari novemb figur jardianc share gain driven posit data
label updat follow posit data empa-reg outcom trial show drug
lower cardiovascular risk increas amputation/fractur risk growth overal
categori slow somewhat rang mid-teen estim
ww invokana/invokamet sale includ us sale yr/yr declin
im trend suggest potenti upsid chang forecast due deterior rx trend
latitud clear posit impact zytiga growth sinc present latitud
data american societi clinic oncolog june zytiga im rx sale growth
meaning rebound latitud show zytiga significantli improv surviv patient
hormone-nav prostat cancer posit growth trend seen novemb like
continu view zytiga trx nrx volum grew respect
novemb vs declin respect april figur zytiga im sale also grow
novemb sale vs flattish low-singl digit growth month prior figur
file latitud data fda septemb suggest label expans
earlier treatment stage like increas us zytiga sale forecast
yr/yr growth forecast ww zytiga sale growth
see latitud continu drive zytiga growth anniversari data like
gener competit weigh significantli busi year although approv
apalutamid help off-set headwind estim jnj overal prostat cancer
franchis sale fall yr/yr view remain decis patent offic
expect time jnj zytiga patent although outcom may chang overal time
howev oral argument summari judgment schedul februari decis
could end stay allow gener market octob
believ worst case scenario current forecast believ earlier launch
apalutamid us prioriti review could help off-set impact earlier gener competit
xarelto rx growth stabl share continu declin novemb eliqui maintain
lead among novel oral anticoagul noac share m/m follow xarelto
share pradaxa share ytd novemb xarelto
lost market share eliqui gain share figur novemb xarelto trx
nrx volum rose slightli mid-teen averag growth ytd octob
figur similarli overal noac market nrx volum grew novemb mid-
averag growth ytd octob noac account oral anticoagul
nrx decemb xarelto launch juli figur
estim us xarelto sale growth seem reason base im trend
believ xarelto growth possibl share could improv addit compass
data label recal file compass data late cad/pad coronari arteri
popul help differenti drug profil among physician payor
jnj long-act atyp franchis growth steadi im sale jnj long-act
inject atyp laia franchis sustenna trinza risperd consta grew novemb in-
line high-teen averag growth figur steadi growth larg reflect strong
growth sustenna trinza off-set low- mid-singl digit declin consta
year trinza sale track larg in-lin sustenna sale time post launch trinza
current account franchis sale franchis growth accord im
note report us laia franchis sale growth vs im sale growth
saw actual growth trail im growth although reason differ remain
unclear us laia market maintain lead risperd consta invega sustenna/trinza
hold nrx share novemb although lost share past year ostuka abilifi
maintena current hold share aristada share figur estim ww
sustena/trinza includ us sale growth could see modest upsid
us estim base recent im sale trend materi enough rais forecast
robust stelara im sale growth continu stelara im sale grew novemb vs
averag averag ytd figur data specialti support crohn
key growth driver monthli written gastroenterolog specialist stelara
increas past year rheumatologist also support continu
stelara growth dermatologist stelara pace declin
modest expect given competit forecast ww stelara sale
includ us sale growth seem reason base recent im sale data
tremfya launch still earli sampl captur im tremfya market
month weekli tremfya volum lag behind stelara nv cosentyx lli taltz
week post-launch figur although launch still earli stage howev rx volum
includ sampl provid pursu full reimburs suggest im may
underst tremfya true ramp continu see tremfya import growth driver jnj
pharma franchis assum stelara growth slow due cannib tremfya
competit cosentyx taltz accord im cosentyx sale annual taltz
sale annual track ahead stelara time post-launch figur
cosentyx/taltz price stelara point post-launch
simponi/aria im sale growth robust novemb novemb simponi im sale rose
vs octob aria im sale grew vs octob lead franchis
growth vs octob novemb fifth consecut month double-digit
franchis im sale growth sinc june figur believ franchis good growth
momentum bode well estim ww simponi/aria sale includ
us sale growth seem reason base recent im sale trend
opsumit tracleer uptravi appear track least in-lin expect
close acquisit atln month ago track im sale trend
top three atln drug opsumit tracleer uptravi figur togeth repres
atln us sale grew caveat track may limit util im
sale histor captur report opsumit/uptravi sale report tracleer sale
estim us opsumit sale pro forma pf growth extrapol
im sale growth direct consist trend report pf growth vs
im sale growth estim us tracleer sale pf declin benign
extrapol im sale declin also direct consist trend
report pf declin vs im sale declin estim us uptravi sale pf
growth ahead extrapol im sale growth base trend report pf
im sale growth similar could see upsid uptravi forecast howev
chang model dont suffici histor trend beyond back test comparison
reportedim us split im health incorpor nation sale perspect compani report secur llc estim sale estim base commentari im data forecast us imbruvica sale assum record end-us sale report consist third month perform prior quarter assum dec im sale repres johnson johnson
compris mostli pfe/celltrion inflectra
figur darzalex share dip line multipl myeloma market
figur darzalex share flattish line multipl myeloma market
rxtrxnrxfeb cll approvedmar front-lin cll approvedjul r/r cll label expans includ mutat jan waldenstrm macroglobulinemia approvedaug graft-vs-host-diseas cgvhd growthmonthli trxtrx volumetrx rx y/i add black box warn leg foot amput present canva data ada meet -posit efficaci safeti trade-off strengthen warn risk acut kidney injuri johnson johnson
figur zytiga monthli volum growth trend improv
new oral anticoagul includ pradaxa xarelto eliqui savaysa
growth trxtrx growthtrx nrxnrxoral anticoagulantsnew oral anticoagul new oral anticoagul xarelto spaf approvedeliqui spaf approvedeliqui dvt prevent approvedsavaysa spaf approvedeliqui dvt treatment approvedxarelto dvt treatment approv johnson johnson
sale month launchinvega sustennarisperd constainvega growthim sale sustenna trinza consta sale yoy im sale growthsustenna launch aug launch jun market sharealk aristadaotsuka abilifi maintenajnj sinvega sustenna trinza risperd consta medic technolog
figur taltz cosentyx launch outpac stelara launch
figur atln opsumit im sale growth continu
figur atln tracleer im sale continu declin
figur atln uptravi im sale remain solid launch trajectori
analysi independ arriv secur llc basi data
inform im respons relianc recipi either data analys
sale trxtrxim salespotenti approv us/eudarzalex alcyon front-lin multipl myeloma us/eu us castration-resist prostat cancer us/eu str d/c/f/tafhiv us metastat prostat cancer us eu edur dolutegravir fdc viiv hiv mainten treatment eu possibl submiss us/euesketaminetreat resist depressiontalacotuzumabacut myeloid leukemia aml niraparibprost cancerstelara line extensionulc coliti uc xarelto line extensionschf mace reduct pad pediatr vte treatmentdarzalex line extensionsmaia cassiopeia front-lin mmimbruvica line extensionsmcl front-lin mainten diffus larg cell lymphoma r/r follicular lymphoma potenti clinic data present base studi primari complet feb genitourinari cancer symposium phase w/ zytiga vs zytiga chemo-nav w/ dacogen vs dacogen onlystelaraunifi uc imbruvicaresolv phase diffus larg cell lymphoma phase mcl front-lin phase treatment-nav follicular lymphomadarzalexmaia w/ revlimid dex front-lin mm cassiopeia transplant elig front-lin mm xarelto explor program command hf chf marin pad einstein junior vte-pediatr galileo post-tavr phase johnson johnson
price target
price target impli cash ep base sum-of-the-part
risk includ delay pipelin product unexpect delay deal integr unexpect
deterior industri
expect overal growth improv multipl tailwind recent acquisit start
contribut organ
johnson johnson world comprehens broadli base manufactur health care
product servic consum pharmaceut medic devic market medic devic
segment consist primarili product cardiovascular orthoped surgic diabet vision
compani report sale year-over-year constant currenc
